Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Kartika : Jurnal Ilmiah Farmasi
Elin Yulinah Sukandar
Program Studi Magister Farmasi, Fakultas Farmasi, Universitas Jenderal Achmad Yani, Cimahi, Indonesia
Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Social Sciences

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
EFEKTIVITAS-BIAYA PENGGUNAAN BEVACIZUMAB DAN RANIBIZUMAB SEBAGAI ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PADA PASIEN DENGAN GANGGUAN MATA: TINJAUAN SISTEMATIS Nur Sidik Cahyono; Elin Yulinah Sukandar
Kartika Jurnal Ilmiah Farmasi Vol 9 No 1 (2024)
Publisher : Fakultas Farmasi Universitas Jenderal Achmad Yani, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.26874/kjif.v9i1.658

Abstract

Anti-vascular endothelial growth factor (VEGF) given by intravitreal injection can be used to treat patients with eye disorders. The anti-VEGF drugs used include bevacizumab, ranibizumab, aflibercept, and brolucizumab. These drugs are high-cost drugs, so the cost-effectiveness of each drug must be considered in order to save on treatment costs. This systematic review aims to provide a comprehensive picture of the cost-effectiveness of bevacizumab and ranibizumab. The databases used to identify relevant studies are PubMed, Science Direct and Google Scholar. This research is limited to randomized control trials (RCT), clinical trials, and research articles, studies that explain the cost-effectiveness of intravitreal injections of bevacizumab and ranibizumab and other drugs as anti-VEGF for patients with eye disorders, as well as articles in English. Electronic data-based searches resulted in 2414 articles; 27 articles were selected that had full text access and discussed the cost-effectiveness of ranibizumab or bevacizumab, but only 12 articles suitable for inclusion were considered. Bevacizumab is more cost-effective than ranibizumab.
STUDI INTERAKSI OBAT-OBAT JANTUNG YANG DILAKUKAN TERHADAP ORANG SEHAT: TINJAUAN SISTEMATIS Yunita Sumartin; Elin Yulinah Sukandar
Kartika Jurnal Ilmiah Farmasi Vol 9 No 2 (2024)
Publisher : Fakultas Farmasi Universitas Jenderal Achmad Yani, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.26874/kjif.v9i2.669

Abstract

Patients with cardiovascular disease have a higher prevalence of drug interactions than other patient groups. Drug interactions may result from pharmacokinetic or pharmacodynamic mechanisms. This study is a systematic review that aims to identify drug interactions related to cardiac drugs. Article searches were conducted on PubMed and ScienceDirect databases to identify all articles on cardiac drug-drug interaction studies. The search started from articles published in 2013 to 2023. The keywords used in the article search were as follows: drug-drug interactions, cardiac patient, cardiac drug, cardiovascular drug, pharmacokinetics interaction, pharmacodynamic interaction combined with the boolean operator "AND". Study articles that met the requirements were entered into the study for review. The total number of articles identified from the database used was 805 articles; 7 duplicate articles were excluded; 84 articles were available in full text; but only 30 articles in accordance with the inclusion were reviewed. Potential drug interactions related to cardiac drugs were most common in the Angiotensin II Receptor Blocker (ARB) class of drugs. Other cardiac drug interactions occurred with angiotensin receptor-neprilysin inhibitors (ARNI), anticoagulants, antiplatelets, digoxin, calcium channel blockers and beta blockers. The effects of these cardiac drug interactions vary. To avoid the occurrence of drug interactions, co-administration of cardiac drugs should be administered with caution, dose adjustments may be required, and monitoring for possible adverse drug events should be done.
Co-Authors Nur Sidik Cahyono Yunita Sumartin